News
November 5, 2018

Antipsychotic drugs do not benefit patients suffering delirium in ICU

Patient on life support in ICU

A new study shows that critically ill patients are not benefiting from antipsychotic medications that doctors have been using to treat delirium in patients in intensive care units. The evidence suggests doctors may need to re-examine the practice. Regenstrief investigator Babar Khan, M.D., was a co-author on the study.

Each year, more than seven million hospitalized patients in the United States develop delirium. The acute brain failure results in confusion and long-term memory problems.

The large study, MIND-USA (Modifying the INcidence of Delirium), sought to answer whether typical and atypical antipsychotics — haloperidol or ziprasidone — affected delirium, survival, length of stay or safety in ICU patients. Researchers screened nearly 21,000 patients at 16 U.S. medical centers. Of the 1,183 patients on mechanical ventilation or in shock, 566 became delirious and were randomized into groups receiving either intravenous haloperidol, ziprasidone or placebo (saline). Results showed that patients who received the drugs did not experience any improvements whatsoever in delirium, coma, length of stay or survival.

Study authors say the medicines are bringing risk and cost without benefit, based on the outcomes measured in this study. Doctors have been prescribing the drugs for 40 years.

Dr. Khan, who worked on this study, has conducted extensive studies on treating and preventing delirium. He led a project at Regenstrief that developed and validated the Confusion Assessment Method for the Intensive Care Unit 7. It’s an easy-to-use method to determine the severity of delirium.

The MIND-USA study was published in the New England Journal of Medicine. It was funded by the National Institute on Aging.

Related News

Regenstrief researchers share innovations in health services at AcademyHealth 2025

Regenstrief researchers share innovations in health services at AcademyHealth 2025

Regenstrief Institute faculty and staff played a prominent role at the 2025 AcademyHealth Annual Research Meeting (ARM) June 7-10

Susan Hickman

Regenstrief and IU leader to depart for Kaiser Permanente

After serving in prominent roles at Regenstrief Institute, Indiana University School of Nursing and the IU School of Medicine,

Addressing social isolation, access to healthcare and well-being

Successful health system, congregation collaboration associated with reduced loneliness and fewer emergency department visits An innovative partnership between a

Research scientist reflects on foundational years of the AMPATH research program

On June 9 during a presentation at Indiana University’s Mini-University in Bloomington, Regenstrief Institute Research Scientist William M. Tierney,